Minnelide suppresses GVHD and enhances survival while maintaining GVT responses

Area of Science:

• Immunology
• Hematology
• Oncology

Background:

• Allogeneic hematopoietic stem cell transplantation (aHSCT) offers curative potential for leukemias and lymphomas.
• Graft-versus-host disease (GVHD) remains a significant limitation to aHSCT efficacy.
• Minnelide, a triptolide analog, exhibits anti-inflammatory and anti-tumor properties.

Purpose of the Study:

• To evaluate Minnelide's efficacy in preventing acute GVHD post-aHSCT.
• To compare Minnelide's effectiveness against posttransplant cyclophosphamide (PTCy).
• To investigate the mechanisms underlying Minnelide's GVHD suppression.

Main Methods:

• Testing Minnelide in MHC-mismatched, minor MHC-matched, and xenogeneic HSCT models.
• Assessing survival, weight loss, clinical GVHD scores, and colonic length.
• Analyzing immune cell populations, including donor T cells and regulatory cells (Tregs, ILC2s, MDSCs).

Main Results:

• Minnelide significantly improved survival and reduced GVHD severity in various HSCT models.
• Minnelide demonstrated comparable efficacy to PTCy in GVHD prevention.
• GVHD suppression was associated with reduced donor T cell infiltration and increased regulatory cell populations.
• Minnelide preserved graft-versus-tumor activity.

Conclusions:

• Minnelide is a potent agent for preventing acute GVHD after aHSCT.
• The mechanism involves modulation of immune cell populations and preservation of anti-leukemia responses.
• Minnelide represents a promising therapeutic strategy for AML patients undergoing aHSCT.